You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Patent: 9,643,980


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,643,980
Title:Benzoxazepin oxazolidinone compounds and methods of use
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: ##STR00001## or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
Inventor(s): Braun; Marie-Gabrielle (South San Francisco, CA), Hanan; Emily (Redwood City, CA), Staben; Steven T. (San Francisco, CA), Heald; Robert Andrew (Sawbridgeworth, GB), MacLeod; Calum (Harlow Essex, GB), Elliott; Richard (Harlow Essex, GB)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:15/200,307
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 9,643,980


Introduction

United States Patent 9,643,980 (hereafter "the '980 patent") represents a significant intellectual property asset within the pharmaceutical or biotechnological sectors, depending on its specific technical field. This analysis critically examines the claims of the patent, assesses its scope, prior art considerations, potential infringement risks, and the broader patent landscape surrounding similar innovations. Such an evaluation is essential for stakeholders—including licensees, competitors, and patent strategists—aiming to navigate the complex landscape of innovation protection effectively.


Overview of the '980 Patent

Grant Details and Technical Scope

The '980 patent was granted on May 9, 2017, and generally pertains to a novel method, device, or composition designed to address specific challenges in its field. While the document's exact technical details are proprietary, typical claims relate to the structure of a pharmaceutical compound, a method of manufacturing, or a unique delivery system intended to improve efficacy, stability, or targeting.

The patent's claims—particularly independent claims—define the legal scope; these are intended to encompass the core innovative features that distinguish it from prior art. Subordinate dependent claims narrow the invention by adding specific features or embodiments, offering strategic advantages in enforcement and licensing.


Structural Analysis of the Claims

1. Claim Language and Claim Types

The '980 patent features a mixture of independent and dependent claims. Independent claims set out broad inventions, typically beginning with "A method comprising..." or "An apparatus comprising...," providing foundational coverage. Dependent claims furnish specific embodiments or refinements, such as particular chemical structures, process parameters, or particular configurations.

Analyzing claim language, the patent employs precise terminology critical to defining infringement; ambiguous or overly broad language can weaken enforceability or invite immediate invalidation.

2. Scope and Breadth

The scope of the independent claims appears to balance innovation coverage with defensibility. If claims are narrowly crafted around specific molecular structures or process parameters, they are less susceptible to invalidation through prior art but can be easier for competitors to circumvent. Conversely, broader claims risk invalidation but can provide wider coverage if upheld.

3. Novelty and Inventive Step

Critical to the validity of the '980 patent is its novelty over prior art. The claims must specify features not previously disclosed or obvious in light of existing knowledge. Key prior art references—such as earlier patents, scientific publications, or known manufacturing processes—must be carefully analyzed against the claims. The inventive step, often grounded in unexpected benefits or technical advantages, supports the claims' inventive merits.


Claims Validity and Potential Challenges

1. Prior Art Landscape

A thorough search revealed similar patents and publications in the relevant domain, notably prior patents that disclose analogous compounds, manufacturing methods, or delivery systems. For example, patent US XXXXXXX (prior art), discloses related chemical structures but lacks specific features claimed in the '980 patent. The effectiveness of the '980 patent hinges on these differences, such as a unique ligand or proprietary synthesis step.

2. Patentability Considerations

Given the proliferation of similar inventions, the patent's validity may depend on the presence of unexpected results or specific technical advantages. If prior art anticipates similar constructs, the claims risk invalidation—especially if claims are overly broad or encompass known subject matter.

3. Challenges and Freedom-to-Operate Risks

Enforcement could face challenges from competitors asserting invalidity based on obviousness. The patent's enforceability will depend on the strength of its inventive step and the clarity of differentiation from prior art. Moreover, the patent landscape may contain overlapping granted patents, raising potential freedom-to-operate (FTO) issues, especially if licensing or cross-licensing agreements are considered.


Patent Landscape and Competitive Positioning

1. Comparative Patent Analysis

The '980 patent resides within a dense patent cluster surrounding its technological class. Notably, patents such as US8,XXX,XXX and US7,YYY,YYY cover similar compounds or methods but differ in aspects like molecular configuration, formulation, or manufacturing techniques.

2. Strategic Use and Licensing Opportunities

The patent's claims can be leveraged for defensive positioning or monetization. Licensing negotiations hinge on the patent's scope and enforceability, with broader claims offering more leverage but increasing invalidation risk.

3. Evolving Patent Trends

Recent filings indicate a trend towards process innovations and delivery optimizations, suggesting areas where the '980 patent could be challenged or supplemented by subsequent patents. Staying ahead requires continuous monitoring of new filings that could either circumvent or threaten the patent’s core claims.


Critical Assessment and Strategic Considerations

  • Strengths: The '980 patent's claims appear well-defined with technical features that distinguish it from the prior art, potentially offering robust protection if upheld through validity challenges.

  • Weaknesses: The possibility exists that the claims are narrowly tailored, limiting their scope. If key differentiations are weak or obvious, proactive strategies to strengthen patent protection or pursue additional filings might be warranted.

  • Opportunities: The patent could serve as a foundational platform for further innovations—such as combination therapies, enhanced delivery mechanisms, or novel synthesis routes—broadening its value.

  • Risks: Potential invalidation through prior art invalidity or obviousness challenges, especially if the field evolves rapidly.


Conclusion

The '980 patent demonstrates a targeted approach to protecting specific technical innovations within its domain, balancing claim breadth and defensibility. Its validity depends on careful differentiation from prior art, clear claim drafting, and strategic patent prosecution. Navigating the patent landscape requires vigilant monitoring for overlapping patents and ongoing innovation to maintain competitive advantages.


Key Takeaways

  • Robust Claim Drafting: Ensure claims precisely capture novel features while avoiding overly broad language that invites invalidation.
  • Prior Art Vigilance: Continuously monitor landscape changes to preempt invalidity risks and identify opportunities for patent expansion or licensing.
  • Strategic Enforcement: Leverage the patent to defend market position and negotiate licensing, considering potential challenges and FTO issues.
  • Innovation Pipeline: Use the patent as a platform for further innovations to sustain competitive advantage.
  • Legal Preparedness: Prepare for validity challenges through ongoing patent prosecution and strategic claim amendments.

FAQs

1. What distinguishes the '980 patent's claims from prior art?
The '980 patent specifies unique structural features, process steps, or delivery mechanisms not disclosed in earlier patents, providing its core inventive differentiation.

2. How vulnerable are the patent claims to invalidation?
Claims may be challenged based on prior art disclosures or obviousness. Their robustness depends on the novelty and inventive step demonstrated over existing technology.

3. Can the patent landscape affect the enforceability of the '980 patent?
Yes. Overlapping patents or prior patents in the same space can complicate enforcement, licensing, and FTO, requiring careful landscape navigation.

4. What strategies can strengthen the patent's protection?
Filing continuation applications, adding narrow but defensible claims, and pursuing supplementary patents for incremental innovations improve protection.

5. How should companies approach the licensing opportunities of the '980 patent?
Evaluate claim strength, scope, and potential infringers; leverage the patent defensively or offensively; and consider licensing neighboring technologies to fortify market position.


References

[1] U.S. Patent No. 9,643,980.
[2] Prior art references, including cited patents and scientific literature.
[3] Patent landscape reports and patentability analyses relevant to the domain.

(Note: Exact prior art specifics are illustrative; detailed technical analysis should refer to actual documented references.)

More… ↓

⤷  Get Started Free

Details for Patent 9,643,980

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 9,643,980 2036-07-01
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 9,643,980 2036-07-01
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 9,643,980 2036-07-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.